Amendment NO. 5 to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 5 (“Amendment No. 5”), with an effective date of as of the date of the last signature (“Amendment No. 5 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. 6 to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 6 (“Amendment No. 6”), with an effective date as of the date of the last signature (“Amendment No. 6 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. NINE (9) to [***] EXCLUSIVE START-UP LICENSE Agreement between Sana biotechnology, Inc. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 9 (“Amendment No. 9”), with an effective the date of last signature (“Amendment No. 9 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. SEVEN (7) to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 7 (“Amendment No. 7”), with an effective date of as of the date of the last signature (“Amendment No. 7 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 2 TO PATENTS SUB-LICENSE AGREEMENTSub-License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Patents Sub-License Agreement (“Amendment No. 2”), effective as of 16 August 2018 (“Amendment No. 2 Effective Date”), is entered into by and between LA SOCIETE PULSALYS, a company organized under French Law, having its registered office at [***] (French company registration number) [***], Code [***] (French principal activity code) [***] (“Pulsalys”) and Sana Biotechnology, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Sana”).
AMENDMENT NO. 2 TO OPTION AND LICENSE AGREEMENTOption and License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Option and License Agreement (the “Second Amendment”) is made as of July 19, 2022 (the “Second Amendment Effective Date”), by and between Beam Therapeutics Inc., a Delaware corporation having an office at 238 Main Street, Cambridge, MA 02142 (“Beam”), and Sana Biotechnology, Inc., a Delaware corporation having an office at 188 E Blaine Street, #400, Seattle, WA 98102 (“Sana”). Sana and Beam are referred to in this Second Amendment individually as a “Party” and collectively as the “Parties”.
Amendment NO. 10 to EXCLUSIVE START-UP LICENSE Agreement between CYTOCARDIA, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 10 (“Amendment No. 10”), with an effective date of the date of last signature (“Amendment No. 10 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. Eight (8) to EXCLUSIVE START-UP LICENSE Agreement between Sana biotechnology, Inc. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 8 (“Amendment No. 8”), with an effective the date of last signature (“Amendment No. 8 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. 11 to EXCLUSIVE START-UP LICENSE Agreement between CYTOCARDIA, INC. and UNIVERSITY OF WASHINGTONOriginal Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 11 (“Amendment No. 11”), with an effective date of the date of last signature (“Amendment No. 11 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
